Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00968825
Other study ID # RT001-CL012LCL
Secondary ID
Status Completed
Phase Phase 2
First received August 27, 2009
Last updated October 25, 2013
Start date July 2009
Est. completion date October 2009

Study information

Verified date October 2013
Source Revance Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of a single administration of RT001 compared to placebo gel for the treatment of moderate to severe lateral canthal lines.


Description:

This is a double-blind, randomized, parallel-group, controlled, multi-center study to evaluate the efficacy and safety of a single administration of RT001 compared to placebo applied as a bilateral application in at least 72 subjects with moderate to severe Lateral Canthal Lines. Subjects will be randomized within each site to 1 of 2 treatment groups in a 1:1 ratio. The efficacy and safety of RT001 compared to placebo will be evaluated. Study follow-up visits will occur at Weeks 2, 4 and 6.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date October 2009
Est. primary completion date October 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria:

- Female or male, 30 to 60 years of age

- Bilateral lateral canthal lines rated as moderate or severe based on the Investigator Global Assessment - Lateral Canthal Lines Rest and Investigator Global Assessment - Lateral Canthal Lines Smile Severity Scales

- Willing to refrain from receiving facial fillers, laser treatments, use of any product that affects skin remodeling or a product that may cause an active dermal response in the treatment area beginning at Screening and through End of Study (Week 6)

- Women of childbearing potential must be practicing and willing to continue to use an effective method of birth control during the course of the study

Exclusion Criteria:

- Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and euromuscular junctional disorders

- Muscle weakness or paralysis in the area receiving study treatment

- Active skin disease or irritation at the treatment areas

- Eyelid ptosis, excessive dermatochalasis, deep dermal scarring or inability to substantially lessen the lateral canthal lines to be treated by physically spreading them apart

- Use of prescription retinoid products during the past 3 months prior to Screening

- Chemical peel (medium depth or deeper) during the past 9 months prior to Screening

- Undergone any procedures that may affect the lateral canthal region such as: periorbital surgery, brow left or related procedures, laser skin resurfacing or soft tissue augmentation (upper half of face) during the past 12 months prior to Screening

- Screening electrocardiogram (ECG) that is abnormal or clinically significant or any history of hypokalemia, torsade de pointe, unstable angina, myocardial infarction or congestive heart failure or family history of prolonged QT

- Previous treatment with Botulinum Toxin Type A in the face area

- Previous treatment with greater than 200 U Botulinum Toxin Type A anywhere else in the body within the last 6 months prior to Screening

- Concurrent use of aminoglycoside antibiotics, or other agents that might interfere with neuromuscular transmission starting at Screening

- Use of a topical steroid on either of the treatment areas or use of medications that suppress the immune system 30 days prior to Screening and continuing through End of Study (Week 6)

- Clinically significant laboratory values at Screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum Toxin Type A
RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
Placebo
Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines

Locations

Country Name City State
United States RGG, Inc San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Revance Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Rest from Baseline (Day 0) to Week 4; incidence of treatment emergent AEs Week 4 No
Secondary The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Rest and Smile from Baseline (Day 0) to Week 4 and Baseline (Day 0) to Week 6; incidence of treatment emergent AEs Week 4 and Week 6 No
See also
  Status Clinical Trial Phase
Completed NCT01447342 - A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines Phase 2/Phase 3
Completed NCT00978887 - Retorna Facial Cream in the Treatment of Facial Wrinkles Phase 3
Completed NCT00414544 - Evaluation of the Safety and Efficacy of CosmetaLifeā„¢ for the Correction of Nasolabial Folds Phase 2
Completed NCT00888914 - Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Phase 2
Completed NCT00877279 - Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft Phase 3
Completed NCT01124565 - Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Phase 2
Completed NCT00922623 - Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI N/A
Not yet recruiting NCT03836638 - The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment N/A
Not yet recruiting NCT06322875 - A Clinical Study to Evaluate the Efficacy and Satisfaction of RHC Serum Combined With RHC(III) Injection N/A
Completed NCT01566396 - Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles N/A
Completed NCT01151436 - Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers N/A
Completed NCT06321770 - Oral Supplementation With Active Collagen Peptides and Skin Health Improvement N/A
Completed NCT01379365 - Cryo-Touch III Refinement Study Investigational Plan Phase 2/Phase 3
Completed NCT00288470 - A Double-blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast. N/A
Completed NCT02122536 - Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles N/A
Completed NCT01167140 - Cryo-Touch II for the Treatment of Wrinkles Phase 2/Phase 3
Completed NCT03286283 - The Use of J-Plasma® for Dermal Resurfacing N/A
Completed NCT01064518 - Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Phase 2
Completed NCT00417469 - A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs) Phase 3
Completed NCT00293163 - A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. Phase 4